At week 12 , GLY+SAL / FP demonstrated non-inferiority to TIO+SAL / FP for trough FEV1 : least square mean treatment difference ( LSMdiff ) -7 mL ( SE 17.4 ) with a lower limit for non-inferiority of -60 mL .